Pfizer Valuation
| PFE Stock | 12.17 0.10 0.83% |
At this time, the company appears to be fairly valued. Pfizer Inc CDR holds a recent Real Value of USD12.43 per share. The prevailing price of the company is USD12.17. Our model determines the value of Pfizer Inc CDR from analyzing the company fundamentals such as Return On Equity of 0.0454, operating margin of 0.33 %, and Shares Outstanding of 16.69 B as well as examining its technical indicators and probability of bankruptcy.
Price Book 1.5709 | Enterprise Value 287.5 B | Enterprise Value Ebitda 14.8306 | Price Sales 3.4651 | Forward PE 8.5837 |
Fairly Valued
Today
Please note that Pfizer's price fluctuation is very steady at this time. Calculation of the real value of Pfizer Inc CDR is based on 3 months time horizon. Increasing Pfizer's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Pfizer is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pfizer Stock. However, Pfizer's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.17 | Real 12.43 | Hype 12.17 | Naive 12.79 |
The intrinsic value of Pfizer's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pfizer's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pfizer Inc CDR helps investors to forecast how Pfizer stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pfizer more accurately as focusing exclusively on Pfizer's fundamentals will not take into account other important factors: Pfizer Cash |
|
Pfizer Total Value Analysis
Pfizer Inc CDR is at this time estimated to have takeover price of 287.47 B with market capitalization of 205.74 B, debt of 10.35 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Pfizer fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
287.47 B | 205.74 B | 10.35 B |
Pfizer Investor Information
The company has price-to-book ratio of 1.57. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pfizer Inc CDR has Price/Earnings To Growth (PEG) ratio of 0.18. The entity last dividend was issued on the 8th of November 2024. Based on the analysis of Pfizer's profitability, liquidity, and operating efficiency, Pfizer Inc CDR is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 21.4 B | 12 B |
|
| |||||
| Operating Income | 3.2 B | 3.4 B |
|
|
Pfizer Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pfizer has an asset utilization ratio of 25.83 percent. This suggests that the Company is making USD0.26 for each dollar of assets. An increasing asset utilization means that Pfizer Inc CDR is more efficient with each dollar of assets it utilizes for everyday operations.Pfizer Profitability Analysis
The company reported the revenue of 58.5 B. Net Income was 2.12 B with profit before overhead, payroll, taxes, and interest of 66.23 B.About Pfizer Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Pfizer Inc CDR. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Pfizer Inc CDR based exclusively on its fundamental and basic technical indicators. By analyzing Pfizer's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Pfizer's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pfizer. We calculate exposure to Pfizer's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pfizer's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 33.5 B | 49 B |
Pfizer Quarterly Retained Earnings |
|
Other Information on Investing in Pfizer Stock
Pfizer financial ratios help investors to determine whether Pfizer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pfizer with respect to the benefits of owning Pfizer security.